SAN DIEGO, June 13, 2018 – ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, will present clinical research data at the American Diabetes Association (ADA) 78th Scientific Sessions, June 22-26 in Orlando.
Poster and oral presentations co-authored by ProSciento scientists include:
- 1038-P – Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements
Category: 12-C Clinical Therapeutics/New Technology – Insulins
Saturday, June 23, 11:30 am, Poster Hall - 1090-P – In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists
Category: 12-D Clinical Therapeutics/New Technology – Non-Insulin Injectables
Sunday, June 24, 12:00 pm, Poster Hall - 1091-P – Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide
Category: 12-D Clinical Therapeutics/New Technology – Non-Insulin Injectables
Sunday, June 24, 12:00 pm, Poster Hall - 1097-P – Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies
Category: 12-D Clinical Therapeutics/New Technology – Non-Insulin Injectables
Sunday, June 24, 12:00 pm, Poster Hall - 1098-P – Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide
Category: 12-D Clinical Therapeutics/New Technology – Non-Insulin Injectables
Sunday, June 24, 12:00 pm, Poster Hall - 1111-P – Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)—Evidence from Preclinical, Modeling, and Clinical Studies
Category: 12-D Clinical Therapeutics/New Technology – Non-Insulin Injectables
Sunday, June 24, 12:00 pm, Poster Hall - 74-OR – Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension
Category: 12-E Clinical Therapeutics/New Technology – Oral Agents
Saturday, June 23, 8:30 am, W304E-H
About ProSciento, Inc.
ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. The company is widely recognized for its scientific and therapeutic expertise, unparalleled experience in metabolism, and utilization of advanced, specialized methodologies for metabolic clinical research. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with a comprehensive and scalable portfolio of services, from strategic planning through completion of early phase clinical drug and device development. Founded in 2003, ProSciento has conducted more than 280 clinical projects for NASH, diabetes and obesity and supported the development of numerous metabolic drugs and devices on the market globally today. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 (858) 663-6148
abby.devine@prosciento.com
For business development inquires:
bd@prosciento.com
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
